- Home
- AEVA vs STTK Comparison
AEVA vs STTK Comparison
Compare AEVA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- STTK
- Stock Information
- Founded
- AEVA 2019
- STTK 2016
- Country
- AEVA United States
- STTK United States
- Employees
- AEVA N/A
- STTK N/A
- Industry
- AEVA Auto Parts:O.E.M.
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- AEVA Consumer Discretionary
- STTK Health Care
- Exchange
- AEVA Nasdaq
- STTK Nasdaq
- Market Cap
- AEVA 2.0B
- STTK 37.6M
- IPO Year
- AEVA N/A
- STTK 2020
- Fundamental
- Price
- AEVA $26.30
- STTK $0.83
- Analyst Decision
- AEVA Buy
- STTK Hold
- Analyst Count
- AEVA 6
- STTK 4
- Target Price
- AEVA $16.20
- STTK $3.00
- AVG Volume (30 Days)
- AEVA 3.4M
- STTK 423.3K
- Earning Date
- AEVA 08-06-2025
- STTK 07-31-2025
- Dividend Yield
- AEVA N/A
- STTK N/A
- EPS Growth
- AEVA N/A
- STTK N/A
- EPS
- AEVA N/A
- STTK N/A
- Revenue
- AEVA $10,326,000.00
- STTK $4,606,000.00
- Revenue This Year
- AEVA $94.59
- STTK N/A
- Revenue Next Year
- AEVA $165.22
- STTK N/A
- P/E Ratio
- AEVA N/A
- STTK N/A
- Revenue Growth
- AEVA 95.90
- STTK 69.65
- 52 Week Low
- AEVA $2.36
- STTK $0.69
- 52 Week High
- AEVA $38.80
- STTK $4.99
- Technical
- Relative Strength Index (RSI)
- AEVA 49.32
- STTK 38.86
- Support Level
- AEVA $28.64
- STTK $0.75
- Resistance Level
- AEVA $34.48
- STTK $0.85
- Average True Range (ATR)
- AEVA 4.09
- STTK 0.09
- MACD
- AEVA -0.96
- STTK -0.01
- Stochastic Oscillator
- AEVA 18.72
- STTK 9.59
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.